Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 4, 2009

Biovail Licenses Acadia's Late-Stage CNS Disease Drug with an Initial Fee of $30M

Biovail acquires license to pimavanserin

  • Biovail Laboratories acquired the U.S. and Canadian rights to develop and market Acadia Pharmaceuticals' pimavanserin tartrate in neurological and psychiatric conditions for $30 million up front. Acadia could earn $365 million in milestons related to development and sales goals.

    Pimavanserin tartrate is a selective 5-HT2A inverse agonist currently in a Phase III study for Parkinson's disorder psychosis (PDP). The drug also completed a Phase II trial in Schizophrenia. Acadia will continue to be responsible for the late-stage PDP investigation, while Biovail will fund an Alzheimer's program.

    Acadia stands to earn $160 million in milestones related to drug development, regulatory submissions, and approval in Alzheimer's and PDP. If a third indication is added, Biovail could pay up to $45 million in success milestones. Acadia could also receive a further $160 in milestones associated with sales. 

    Biovail will also make tiered, royalty payments to Acadia on net commercial sales: 15% on annual sales of up to $100 million and 20% on sales greater than $100 million. Biovail will assume all costs associated with the development, manufacturing, and commercialization of pimavanserin in all indications save specified ongoing studies, which Acadia will fund.ADNFCR-2184-ID-19152011-ADNFCR


    Related Articles

    Acadia to Develop Schizophrenia Treatments with Meiji Seika for Asian Market (Mar. 25, 2009)
    Biovail Acquires Prestwick for $100M Gaining Approved Drug in CNS Indication (Sept. 17, 2008)
    Biovail Gains License to Two Pharma Pass II Early-Stage Compounds (Nov. 7, 2007)
    Biovail Settles Infringement Case Related to Wellbutrin XL (Mar. 5, 2007)
    Depomed Grants Biovail License to Drug Delivery Technology (Feb. 12, 2007)

Related content